IDH2 inhibition in AML: Finally progress? Journal Article


Author: Stein, E. M.
Article Title: IDH2 inhibition in AML: Finally progress?
Abstract: Isocitrate dehydrogenase (IDH) catalyzes the conversion of isocitrate to alpha ketoglutarate. IDH occurs in three isoforms, IDH1, located in the cytoplasm, IDH2 located in the mitochondria, and IDH3, which functions as part of the TCA cycle. Mutations in the active site of IDH1 at position R132 and an analogous mutation in the IDH2 gene at position R172 have been discovered. Notably, many cases of acute myeloid leukemia (AML) have mutations in R172 and R140. The impact of these mutations and early results of inhibiting mutant IDH2 with the reversible inhibitor AG-221 are discussed in this review. © 2015 Published by Elsevier Ltd.
Keywords: isocitrate dehydrogenase; acute myeloid leukemia; 2-hg
Journal Title: Best Practice and Research: Clinical Haematology
Volume: 28
Issue: 2-3
ISSN: 1521-6926
Publisher: Elsevier Inc.  
Date Published: 2015-06-01
Start Page: 112
End Page: 115
Language: English
DOI: 10.1016/j.beha.2015.10.016
PROVIDER: scopus
PUBMED: 26590767
DOI/URL:
Notes: Article -- Export Date: 4 April 2016 -- Source: Scopus
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
  1. Eytan Moshe Stein
    342 Stein